Zhou J, et al. - Based on PUBMED and EMBASE, researchers conducted a comprehensive literature search in April 2019 to ascertain if aspirin could decrease the risk of prostate cancer-specific mortality (PCSM). In total, 10 eligible articles were used. Using random-effects models of DerSimonian and Laird, pooled HRs were calculated. According to this systematic review and meta-analysis, no significant link was found between aspirin use and the risk of PCSM. At the same time, there was no statistical effect on the risk of PCSM in high/low risk PC on the dosage and duration of aspirin use. To validate the results, further studies are required.